Evaluation des effets cardiovasculaires du liraglutide: conception et donnees de base de l'etude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER®)

Translated title of the contribution: Design of the Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER® trial)

M. Marre, S. P. Marso, N. R. Poulter, S. E. Nissen, M. A. Nauck, B. Zinman, G. H. Daniels, S. Pocock, W. M. Steinberg, R. M. Bergenstal, J. F E Mann, L. Steen Ravn, K. Brown Frandsen, A. C. Moses, J. B. Buse

Research output: Contribution to journalArticlepeer-review

Abstract

LEADER® (Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcomes results) is a clinical trial evaluating the long-term effect of liraglutide on the incidence of cardiovascular events among 9 340 patients with type 2 diabetes at high cardiovascular risk. The primary endpoint was the occurrence of cardiovascular death, nonfatal myocardial infarction, or stroke. Patients, naive or treated with conventional diabetes therapy, were randomized 1:1 to receive liraglutide or placebo, and followed up to 5 years after randomization. LEADER® design is presented here.

Translated title of the contributionDesign of the Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER® trial)
Original languageFrench
Pages (from-to)316-328
Number of pages13
JournalMedecine des Maladies Metaboliques
Volume9
Issue number3
DOIs
StatePublished - 2015

Keywords

  • GLP-1 receptor agonists
  • Liraglutide
  • cardiovascular.
  • type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Design of the Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER® trial)'. Together they form a unique fingerprint.

Cite this